![](https://news.europawire.eu/wp-content/uploads/2020/10/Wet-Macular-Degeneration-Promising-data-for-Novartis-Beovu-unveiled-at-EURETINA-144x144.jpg)
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1 Patients with early persistent fluid treated with Beovu experienced greater … Read the full press release